跳至主要内容
临床试验/CTRI/2025/10/096638
CTRI/2025/10/096638尚未招募不适用

A cross-sectional study to assess mild cognitive impairment (MCI) and anxiety in Type 2 diabetes mellitus patients and the role of TLR4-NFKB signaling pathway in type diabetes mellitus

Jamia Hamdard1 个研究点 分布在 1 个国家目标入组 332 人开始时间: 2025年11月11日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
Jamia Hamdard
入组人数
332
试验地点
1

研究概览

简要总结

This study aims to investigate SERUM BIOMARKERS INCLUDING HMGB1 and TMAO for their role in Anxiety and Beta 2 microglobulin and claudin-5 as potential indicators of blood brain barrier disruption.YKL-40 Neuroinflammatory biomarker will be assesed to explore the contribution of neuroinflammation to both anxiety and mild cognitive impairment in T2DM.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)

入选标准

  • Inclusion criteria for T2DM
  • Patients attending medicine OPD who had chronic T2DM of more than 3 years.
  • Age 18-65 years
  • Gender (Males, Females, Other)
  • Willingness to provide informed consent
  • Patients suffering from T2DM related MCI assessed using MMSE and MoCA
  • Patients suffering from T2DM related anxiety assessed using HAM-A Inclusion criteria for Healthy Control
  • Patients having MMSE or MoCA scores more than 25
  • Patients without diagnosed T2DM, Anxiety and MCI and any other disease.

排除标准

  • Exclusion Criteria: 1.) Individuals with other comorbidities such as dementia, AD, etc.
  • 2.) Clinical kidney or liver disease 3.) Current use of antibiotics or probiotics 4.) Pregnant and lactating females 5.) Patients with viral or bacterial infections.

研究者

发起方
Jamia Hamdard
申办方类型
Research institution
责任方
Principal Investigator
主要研究者

Dr Nilanjan Saha

Jamia Hamdard

研究点 (1)

Loading locations...

相似试验